Clinical Trials for Topotecan (hycamtin) Oral
1 Open Trial
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | VICCTHN1212 09/12/2012 | Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients with Relapsed Small Cell Lung Cancer (SCLC) |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
